Ahmad Musa, MD
General Practice · Pauls Valley, OKNPI 1144840661
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,546 of the $2,482 with a category attached, or 62.3%. Astrazeneca UK Limited accounts for 77.0% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $1,957 and has fallen 78.8% since, to $415 in 2025. Among general practice clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 31 payments — averaging $80.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$2K
- AstraZeneca$193
- Dexcom, Inc.$106
- Smith+Nephew$52
- GSK$34
- E.r. Squibb & Sons, L.L.C.$27
- plus $160 from 9 others
Across 82 payments — averaging $5605.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$229K
- AstraZeneca$148K
- Pfizer$52K
- Sanofi US Services Inc.$31K
What the payments were for
- Travel & lodging$1,54662%
- Food & beverage$93538%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 9 | $1,910 |
| AstraZeneca | 4 | $193 |
| Dexcom, Inc. | 2 | $106 |
| Smith+Nephew | 3 | $52 |
| GSK | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Globus Medical | 1 | $24 |
| Sanofi | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Amgen | 1 | $17 |
| Pfizer | 1 | $17 |
| Merck | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$122
How this compares
$2,482 in reported general payments places this provider in the 90th percentile of 1,086 general practice providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 215 | $243,381 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 87 | $67,788 |
| JardianceEmpagliflozin | 54 | $52,130 |
| EliquisApixaban | 40 | $34,276 |
| TrulicityDulaglutide | 26 | $28,683 |
| JanuviaSitagliptin Phosphate | 24 | $22,693 |
| FarxigaDapagliflozin Propanediol | 20 | $15,830 |
| SymbicortBudesonide/Formoterol Fumarate | 53 | $15,314 |
| EntrestoSacubitril/Valsartan | 15 | $13,127 |
| MounjaroTirzepatide | 11 | $12,101 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,172 |
| Spiriva RespimatTiotropium Bromide | 11 | $6,429 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $5,918 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 177 | $5,236 |
| Gabapentin | 317 | $4,809 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $34 | $67,78887 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $193 | $40,31788 claims |
| PfizerEliquis | $17 | $34,27640 claims |
| MerckJanuvia | $16 | $22,69324 claims |
| NovartisEntresto | $14 | $13,12715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,086 general practice providers in Oklahoma.
Other general practice in Pauls Valley
- Wesley HodgeBroken Arrow$1.2M
- Joseph MassadTulsa$783K
- Stephen BuchananOklahoma City$123K
- Jennie HunnewellOklahoma City$26K
- Kylie ParrishOklahoma City$19K
- Charles McQuiggJay$18K
- Sandy GraceOklahoma City$14K
- Justin EmamiTulsa$14K
- Michael FlingOklahoma City$13K
- Jon HopkinsShawnee$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.